

# Procizumab (PCZ; AK1967) in Critical Cardiovascular Care

NCT06832722

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	4TEEN4 Pharmaceuticals GmbH
<b>Enrollment</b>	130 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Signed informed consent.
- Diagnosis of CS due to ACS or CS of septic origin based on the following entry criteria:
- Need for ongoing vasopressors and/or to maintain a MAP  $\geq$  65 mmHg or SBP  $\geq$  90 mmHg
- Serum lactate  $\geq$  2.0 mmol/L
- Elevated DPP3 concentration

### Exclusion (33)

- Patients who will be receiving vasopressors and/or inotropes for more than 16 hours prior to receiving the IMP.
- Patients below the age of 18 or above 75 years.
- Patients receiving Ang II and/or Levosimendan.
- Patients with known allergies or hypersensitivity to the IMP or its excipients (including known lactose hypersensitivity) or any related medication.
- Stroke or transient ischemic attack within the last 3 months.

... and 28 more (see full listing online)

## Locations (16 total)

---

Heart Center Aalst, AZORG, Aalst, Belgium  
University Hospital Saint Pierre, Brussels, Belgium  
University Hospital and Medical Faculty of Pilsen, Pilsen, Czechia  
... and 13 more locations